长期恩替卡韦治疗对慢性乙型肝炎患者肾功能的影响

张青; 张飙; 王培; 李颍; 颜学兵; 丁芹

doi:10.3969/j.issn.1001-5256.2020.07.010

长期恩替卡韦治疗对慢性乙型肝炎患者肾功能的影响

DOI: 10.3969/j.issn.1001-5256.2020.07.010

1. 徐州医科大学附属医院感染性疾病科
2. 淮安市第四人民医院感染性疾病科

基金项目:

国家自然科学基金资助项目(81371867)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1923
- HTML全文浏览量: 68
- PDF下载量: 214
- 被引次数: 1
出版历程
- 收稿日期: 2019-12-29
- 出版日期: 2020-07-20

Influence of long-term entecavir treatment on renal function in patients with chronic hepatitis B

Department of Infectious Diseases,The Affiliated Hospital of Xuzhou Medical University
Department of Infectious Diseases,Huai'an Fourth People's Hospital

Research funding:

摘要

摘要: 目的探讨长期应用ETV抗病毒治疗对慢性乙型肝炎（CHB）患者肾功能的影响。方法回顾性分析2015年1月-2019年6月在淮安市第四人民医院接受ETV抗病毒治疗半年以上的CHB患者232例。按不同性别、年龄（<或≥65岁）、有无肝硬化和肾小球滤过率（e GFR）(<或≥90 ml·min-1·1.73 m-2)分组,探讨各个亚组的ETV治疗前后的肾功能指标[血尿素氮（BUN）、血肌酐（Scr）和e GFR]变化情况。并比较ETV抗病毒方案在抗病毒前后总体ALT、AST、Alb、HBs Ag、HBV DNA和肾功能指标（BUN、Scr和e GFR）变化。采用全自动生化分析仪检测血生化指标,包括ALT、AST、Alb、BUN、Scr和e GFR,采用实时荧光定量PCR法检测HBV DNA,采用罗氏电化学发光法检测血清HBs Ag定量。正态分布的计量资料组间比较采用配对t检验,非正态分布的计量资料组间比较采用Wilcoxon秩和检验,采用二分类logistic回归分析筛选ETV抗病毒治疗后e GFR <90 ml·min-1·1. ...
- 乙型肝炎,慢性 /
- 治疗学 /
- 恩替卡韦 /
- 肾功能不全
Abstract: Objective To investigate the influence of long-term entecavir( ETV) antiviral therapy on renal function in patients with chronic hepatitis B( CHB). Methods A retrospective analysis was performed for the clinical data of 232 CHB patients who received ETV antiviral therapy for more than half a year in Huai'an Fourth People's Hospital from January 2015 to June 2019. The patients were divided into groups according to sex,age( < 65 years or ≥65 years),presence or absence of liver cirrhosis,and estimated glomerular filtration rate( eGFR)( < 90 ml/min/1. 73 m2 or ≥90 ml/min/1. 73 m2),and the changes in renal function markers[blood urea nitrogen( BUN),serum creatinine( SCr),and eGFR] after treatment were observed for each group. The changes in alanine aminotransferase( ALT),aspartate aminotransferase( AST),albumin( Alb),HBsAg,HBV DNA,and renal function markers( BUN,SCr,and eGFR) after ETV antiviral therapy were also observed. An automatic biochemical analyzer was used to measure biochemical parameters including ALT,AST,Alb,BUN,SCr,and eGFR; RT-qPCR was used to measure HBV DNA; Roche electrochemical luminescence was used to measure serum HBsAg quantification. The paired t-test was used for comparison of normally distributed continuous data between groups,and the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between groups; a binary logistic regression analysis was used to identify the risk factors for eGFR < 90 ml/min/1. 73 m2 after ETV antiviral therapy. Results After ETV antiviral therapy for more than half a year,there were significant reductions in ALT,AST,HBs Ag,and HBV DNA( Z =-9. 496 and-9. 577,t = 5. 013 and20. 777,all P < 0. 05) and a significant increase in Alb( t =-10. 832,P < 0. 05); compared with baseline,there were significant increases in BUN and SCr( t =-2. 685 and-2. 376,both P < 0. 05) and a significant reduction in e GFR( t = 3. 207,P < 0. 05). Further analysis of each subgroup showed that the e GFR ≥90 ml/min/1. 73 m2 group,the non-elderly group,the liver cirrhosis group,and the male group had significant increases in BUN( t =-3. 403,-3. 187,-2. 267,and-2. 187,all P < 0. 05) and SCr( t =-3. 716,-3. 614,-2. 291,and-2. 115,all P < 0. 05) and a significant reduction in e GFR( t = 4. 846,4. 152,2. 458,and 2. 946,all P < 0. 05),and the non-liver cirrhosis group had a significant reduction in e GFR( t = 2. 163,P < 0. 05) and had no significant changes in BUN and SCr( P >0. 05). The binary logistic regression analysis showed that with the increase in glucose level( odds ratio [OR]= 1. 296,95% confidence interval [Cl]: 1. 052-1. 597,P = 0. 015) and the reduction in total cholesterol( TC)( OR = 0. 436,95% Cl: 0. 286-0. 664,P <0. 001),the risk of e GFR < 90 ml/min/1. 73 m2 increased after ETV therapy. Conclusion ETV antiviral therapy can effectively reduce ALT,AST,HBs Ag,and HBV DNA and increase Alb,but it can cause the increases in BUN and SCr and the reduction in e GFR in patients with e GFR > 90 ml/min/1. 73 m2,non-elderly patients,and patients with liver cirrhosis. Blood glucose and TC are influencing factors for eGFR < 90 ml/min/1. 73 m2 after ETV therapy.
- hepatitis B,Chronic /
- therapeutics /
- entecavir /
- renal insufficiency

HTML全文

参考文献(23)

[1]IDILMAN R.Management of special patient groups with hepatitis Bvirus infection:The EASL 2017 clinical practice guidelines[J].Turk J Gastroenterol,2017,28(6):518-521．

[2]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J CIin Hepatol,2015,32(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,32(12):1941-1960．

[3]OU H,CAI S,LIU Y,et al.A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B[J].Therap Adv Gastroenterol,2017,10(2):207-217．

[4]CAI SH,LU SX,LIU LL,et al.Increased expression of hepatocyte nuclear factor 4 alpha transcribed by promoter 2 indicates a poor prognosis in hepatocellular carcinoma[J].Therap Adv Gastroenterol,2017,10(10):761-771．

[5]YANG YM,CHOI EJ.Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection[J].Ther Clin Risk Manag,2017,13:1273-1285．

[6]LIM L,THOMPSON A,PATTERSON S,et al.Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy[J].Liver Int,2017,37(6):827-835．

[7]YANG X,MA Z,ZHOU S,et al.Multiple drug transporters are involved in renal secretion of entecavir[J].Antimicrob Agents Chemother,2016,60(10):6260-6270．

[8]CIHLAR T,HO ES,LIN DC,et al.Human renal organic anion transporter 1(h OAT1)and its role in the nephrotoxicity of antiviral nucleotide analogs[J].Nucleosides Nucleotides Nucleic Acids,2001,20(4-7):641-648．

[9]MANDKOVJ,VOLKOVM,PVEK P,et al.Entecavir interacts with influx transporters h OAT1,h CNT2,h CNT3,but Not with h OCT2:The potential for renal transporter-mediated cytotoxicity and drug-drug interactions[J].Front Pharmacol,2015,6:304．

[10]FUJII T,KAWASOE K,OHTA A,et al.A case of entecavir-induced Fanconi syndrome[J].CEN Case Rep,2019,8(4):256-260．

[11]WU IT,HU TH,HUNG CH,et al.Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia:A retrospective cohort study[J].Clin Microbiol Infect,2017,23(7):464-469．

[12]WU X,CAI S,LI Z,et al.Potential effects of telbivudine and entecavir on renal function:A systematic review and meta-analysis[J].Virol J,2016,13:64．

[13]LIN YS,SHIH SC,WANG HY,et al.Comparison of telbivudine and entecavir on the change of off-treatment e GFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients[J].BMC Gastroenterol,2017,17(1):22．

[14]HE P,ZHANG D,LI H,et al.Hepatitis B virus X protein modulates apoptosis in human renal proximal tubular epithelial cells by activating the JAK2/STAT3 signaling pathway[J].Int J Mol Med,2013,31(5):1017-1029．

[15]ZHANG JB,GUO HH.Research advances in hepatitis B cirrhosis with renal injury and the application of antiviral drugs[J].J CIin Hepatol,2019,35(1):191-196.(in Chinese)张洁冰，郭宏华．乙型肝炎肝硬化合并肾损伤及抗病毒药物的应用[J]．临床肝胆病杂志，2019,35(1):191-196．

[16]ZHENG S,LIU L,LU J,et al.Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection:A 2-year prospective study[J].Medicine(Baltimore),2019,98(42):e17590．

[17]NEUGARTEN J,ACHARYA A,SILBIGER SR.Effect of gender on the progression of nondiabetic renal disease:A meta-analysis[J].JAm Soc Nephrol,2000,11(2):319-329．

[18]BRAR A,MARKELL M.Impact of gender and gender disparities in patients with kidney disease[J].Curr Opin Nephrol Hypertens,2019,28(2):178-182．

[19]LIMA-POSADA I,PORTAS-CORTS C,PREZ-VILLALVAR,et al.Gender differences in the acute kidney injury to chronic kidney disease transition[J].Sci Rep,2017,7(1):12270．

[20]KRAUTBAUER S,WIEST R,LIEBISCH G,et al.Associations of systemic sphingolipids with measures of hepatic function in liver cirrhosis are related to cholesterol[J].Prostaglandins Other Lipid Mediat,2017,131:25-32．

[21]YAN LT,WANG LL,YAO J,et al.Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection[J].Medicine(Baltimore),2020,99(8):e19248．

[22]LIU Y,FAN R,CHEN J,et al.Assessment of renal function and risk factors for renal impairment in patients with hepatitis B virus-related liver cirrhosis[J].J South Med Univ,2014,34(4):472-476.(in Chinese)刘颖，樊蓉，陈简，等．慢性乙型肝炎病毒感染相关肝硬化患者的肾功能及危险因素分析[J]．南方医科大学学报，2014,34(4):472-476．

[23]CHEN YC,SU YC,LI CY,et al.13-year nationwide cohort study of chronic kidney disease risk among treatment-na6ve patients with chronic hepatitis B in Taiwan[J].BMC Nephrol,2015,16:110.

施引文献